EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic

Mohamad Suki, Ashraf Imam iD, Johnny Amer, Yael Milgrom iD, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon iD, Yousra Sharif, Joseph Sackran, Revital Alon, Nachum Lourie und 6 weitere

Pharmaceuticals · 26.07.2025 · 18 (8) · 1118

DOI: 10.3390/ph18081118 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 26.07.2025. Verfasst von Mohamad Suki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Institution of Liver Diseases, Hadassah Medical Organization, Hadassah-Hebrew University, Jerusalem 91120, Israel. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hadassah Medical Organization.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have shown promise in metabolic dysfunction-associated steatotic liver disease (MASLD). This large real-world study aimed to evaluate the effects of SGLT2 inhibitors on MASLD patients’ clinical outcomes and liver-related complications over extended follow-up. Patients and Method: Data were sourced from TriNetX, a global health research platform with de-identified electronic medical records spanning 135 million patients across 112 healthcare organizations worldwide. We included MASLD adults diagnosed according to ICD9/10 criteria. Following propensity score matching based on 34 variables (demographics, comorbidities, laboratory tests and medication history), SGLT2 inhibitor-treated (n = 19,922) patients were compared with non-SGLT2 inhibitor (n = 19,922) cases. Exclusion criteria included baseline improved alanine aminotransferase (ALT) and alkaline phosphatase (ALP) levels > 4 upper normal limit (UNL), baseline advanced liver disease, liver transplant and cancer, past anticoagulation and non-MASLD etiologies. Assessed outcomes included survival, biochemical, hematologic, AFP, metabolic and cardiovascular parameters, progression to advanced liver disease (ALD), synthetic function, and metabolic markers over 1, 5, and 10 years.

Results

Following matching, both cohorts were well-balanced across baseline characteristics. After one year, the SGLT2 inhibitor group demonstrated significantly reduced BMI (33.2 ± 6.2 vs. 34.1 ± 6.5 kg/m2, p < 0.001), improved ALT (40.3 ± 31.5 vs. 48.3 ± 41.2 U/L, p < 0.001), and better glycemic control (HbA1c 7.35 ± 1.51% vs. 7.93 ± 1.72%, p < 0.001). The SGLT2 inhibitor group showed higher 10-year survival rates (95.00% vs. 88.69%, p < 0.001), fewer cardiovascular events (10.19% vs. 11.80%, p < 0.001), and markedly reduced progression to advanced liver disease (6.90% vs. 14.15%, p < 0.001). These benefits were consistent across clinical, laboratory, and medication-defined ALD categories. Notably, rates of hepatic decompensation events were significantly lower with SGLT2 inhibitor therapy.

Conclusions

In this large real-world cohort, SGLT2 inhibitor use in MASLD patients was associated with significantly improved long-term survival, cardiovascular, and liver-related outcomes over 10 years of follow-up. These benefits likely result from combined metabolic improvements, anti-inflammatory effects, and direct hepatoprotective mechanisms. SGLT2 inhibitors represent a promising therapeutic strategy for improving outcomes in MASLD.

Schlagwörter

Stichwörter der Autor:innen

MASLDNAFLDSGLT2 inhibitorscirrhosisliver outcomesmortality

Autor:innen und Institutionen

  • Institution of Liver Diseases, Hadassah Medical Organization, Hadassah-Hebrew University, Jerusalem 91120, Israel.
  • Transplantation Unit, Department of Surgery, Hadassah Medical Organization, Hadassah-Hebrew University, Jerusalem 91120, Israel.

ORCID-Profile: Ashraf Imam, Yael Milgrom, Ofer Perzon, Anat Hershko Klement, Abed Khalaileh, Rifaat Safadi

Förderung

  • Hadassah Medical Organization

Zitieren

APA

Suki, M., Imam, A., Amer, J., Milgrom, Y., Massarwa, M., Hazou, W., Tiram, Y., Perzon, O., Sharif, Y., Sackran, J., Alon, R., Lourie, N., Hershko Klement, A., Shibli, S., Safadi, T., Raz, I., Khalaileh, A., & Safadi, R. (2025). SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals, 18(8), 1118. https://doi.org/10.3390/ph18081118

Vancouver

Suki M, Imam A, Amer J, Milgrom Y, Massarwa M, Hazou W, et al. SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic. Pharmaceuticals. 2025;18(8):1118. doi:10.3390/ph18081118

BibTeX
@article{Suki2025,
  author = {Suki, Mohamad and Imam, Ashraf and Amer, Johnny and Milgrom, Yael and Massarwa, Muhammad and Hazou, Wadi and Tiram, Yariv and Perzon, Ofer and Sharif, Yousra and Sackran, Joseph and Alon, Revital and Lourie, Nachum and Hershko Klement, Anat and Shibli, Safa and Safadi, Tamer and Raz, Itamar and Khalaileh, Abed and Safadi, Rifaat},
  title = {SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic},
  journal = {Pharmaceuticals},
  year = {2025},
  volume = {18},
  number = {8},
  pages = {1118},
  doi = {10.3390/ph18081118}
}
Kostenlos starten →